Brookline Capital Markets Estimates MRKR Q3 Earnings

Marker Therapeutics, Inc. (NASDAQ:MRKR) – Equities researchers at Brookline Capital Markets increased their Q3 2026 earnings per share (EPS) estimates for shares of Marker Therapeutics in a note issued to investors on Saturday, August 15th. Brookline Capital Markets analyst L. Cann now anticipates that the company will earn ($0.07) per share for the quarter, up from their previous estimate of ($0.44). The consensus estimate for Marker Therapeutics’ current full-year earnings is ($1.17) per share. Brookline Capital Markets also issued estimates for Marker Therapeutics’ Q4 2026 earnings at ($0.32) EPS, FY2026 earnings at ($0.65) EPS and FY2027 earnings at ($1.57) EPS.

A number of other brokerages have also recently issued reports on MRKR. HC Wainwright reissued a “buy” rating on shares of Marker Therapeutics in a report on Wednesday, May 20th. Weiss Ratings lowered shares of Marker Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, August 6th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Marker Therapeutics presently has an average rating of “Hold” and a consensus target price of $10.00.

Marker Therapeutics Price Performance

Shares of NASDAQ:MRKR opened at $1.15 on Wednesday. The business’s fifty day moving average price is $1.31 and its two-hundred day moving average price is $1.41. Marker Therapeutics has a fifty-two week low of $0.81 and a fifty-two week high of $2.46. The stock has a market capitalization of $19.17 million, a price-to-earnings ratio of -2.80 and a beta of 1.50.

Marker Therapeutics (NASDAQ:MRKR) last issued its earnings results on Friday, August 14th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.16. Marker Therapeutics had a negative return on equity of 53.33% and a negative net margin of 343.03%.

Institutional Trading of Marker Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Jane Street Group LLC bought a new position in shares of Marker Therapeutics in the second quarter valued at about $33,000. Virtu Financial LLC bought a new stake in Marker Therapeutics during the 3rd quarter worth about $25,000. Two Sigma Investments LP bought a new stake in Marker Therapeutics during the 3rd quarter worth about $33,000. Boyer Financial Services Inc. acquired a new stake in Marker Therapeutics in the 4th quarter valued at about $57,000. Finally, XTX Topco Ltd increased its position in Marker Therapeutics by 166.6% in the 4th quarter. XTX Topco Ltd now owns 58,041 shares of the company’s stock valued at $86,000 after acquiring an additional 36,269 shares in the last quarter. 22.39% of the stock is currently owned by institutional investors and hedge funds.

About Marker Therapeutics

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.